If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX(1-800-545-5979)
Mounjaro™ (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mgThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Tirzepatide: Use in Patients With Gastroparesis
Tirzepatide has not been studied in people with delayed gastric emptying.
cFAQ
cFAQ
US_cFAQ_TZP320_USE_IN_PATIENTS_WITH_GASTROPARESIS
en-US
Detailed Information
There is no information on the use of tirzepatide in people with gastroparesis because patients were excluded from tirzepatide clinical trials if they had a known clinically significant gastric emptying abnormality (for example, severe diabetic gastroparesis or gastric outlet obstruction).
Date of Last Review: February 05, 2021
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon – Friday, 9am-7pm (EST), excluding holidays